公开(公告)号：US20240000928A1

公开(公告)日：2024-01-04

申请号：US18069489

申请日：2022-12-21

Applicant: OnkosXcel Therapeutics, LLC

Inventor： Luca RASTELLI ,  Aparna Katoch SAPRA ,  Vimal MEHTA

IPC: A61K39/395 ,  A61K38/04 ,  C12N15/113 ,  A61K45/06 ,  A61K31/69 ,  C07K16/28

CPC classification number: A61K39/3955 ,  A61K38/04 ,  C12N15/1137 ,  A61K45/06 ,  A61K39/39541 ,  A61K31/69 ,  C07K16/2818 ,  A61K2039/505

Abstract: The present invention discloses a method of treating, preventing or ameliorating tumor growth by administering a therapeutic agent that selectively inhibits dipeptidyl peptidase including fibroblast activation protein and dipeptidyl peptidase 8/9 in combination with an immune checkpoint inhibitor. The method specifically discloses use of Talabostat in combination with an immune checkpoint inhibitor, its pharmaceutical composition and process of preparing such composition.

公开(公告)号：US11613785B2

公开(公告)日：2023-03-28

申请号：US16476420

申请日：2018-01-09

Applicant: OnkosXcel Therapeutics, LLC

Inventor： Krishnan Nandabalan ,  Luca Rastelli

IPC: C12Q1/6886 ,  G16B25/10

Abstract: The present invention generally relates to a method of diagnosing, prognosing and treating prostate cancer patients. Particularly, the present invention relates to a method of selecting patients with castration resistant prostate cancer (CrPC) for combination therapy comprising a selective dipeptidyl peptidase inhibitor and a PD-1 axis antagonist. The present invention provides a computational approach to identifying potential patients for CrPC. The present invention also relates to a method of treating castration resistant prostate cancer (CrPC) patients with said combination therapy.

公开(公告)号：US20230227918A1

公开(公告)日：2023-07-20

申请号：US18157717

申请日：2023-01-20

Applicant: OnkosXcel Therapeutics, LLC

Inventor： Krishnan NANDABALAN ,  Luca RASTELLI

IPC: C12Q1/6886 ,  G16B25/10

CPC classification number: C12Q1/6886 ,  G16B25/10 ,  C12Q2600/118 ,  C12Q2600/158

Abstract: The present invention generally relates to a method of diagnosing, prognosing and treating prostate cancer patients. Particularly, the present invention relates to a method of selecting patients with castration resistant prostate cancer (CrPC) for combination therapy comprising a selective dipeptidyl peptidase inhibitor and a PD-1 axis antagonist. The present invention provides a computational approach to identifying potential patients for CrPC. The present invention also relates to a method of treating castration resistant prostate cancer (CrPC) patients with said combination therapy.

公开(公告)号：US11564986B2

公开(公告)日：2023-01-31

申请号：US15467781

申请日：2017-03-23

Applicant: ONKOSXCEL THERAPEUTICS, LLC

Inventor： Luca Rastelli ,  Aparna Katoch Sapra ,  Vimal Mehta

IPC: A61K39/395 ,  A61K31/69 ,  A61K39/00 ,  C07K16/28 ,  A61K38/04 ,  C12N15/113 ,  A61K45/06

Abstract: The present invention discloses a method of treating, preventing or ameliorating tumor growth by administering a therapeutic agent that selectively inhibits dipeptidyl peptidase including fibroblast activation protein and dipeptidyl peptidase 8/9 in combination with an immune checkpoint inhibitor. The method specifically discloses use of Talabostat in combination with an immune checkpoint inhibitor, its pharmaceutical composition and process of preparing such composition.